Nicholas P. Alvarez
Known title: Chief Acquisition OfficerCIK: 0001802844
Nicholas P. Alvarez's purchase track record
Nicholas P. Alvarez has only 1 open-market purchase with a full 6 months of price history after it -- too few to call a track record yet.
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 6/14/2023 | LFMD | $31K | +57.7% | +154.4% | +7.6% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Transaction History
| LFMD | ▼ Sell | Open Market | 75,000 | $444K | 9/10/2025 | View on chart |
| LFMD | ▲ Buy | Grant | 100,000 | $0 | 8/22/2025 | View on chart |
| LFMD | ▲ Buy | Grant | 75,000 | $0 | 3/31/2025 | View on chart |
| LFMD | ▲ Buy | Grant | 75,000 | $0 | 3/21/2024 | View on chart |
| LFMD | ▲ Buy | Grant | 100,000 | $0 | 3/7/2024 | View on chart |
| LFMD | ▲ Buy | Grant | 150,000 | — | 7/12/2023 | View on chart |
| LFMD | ▲ Buy | Open Market | 10,712 | $31K | 6/14/2023 | View on chart |
| LFMD | ▼ Sell | Gift | 60,000 | $0 | 2/11/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 27, 2026
LifeMD Announces Preferred Dividend and AT&T Partnership
LifeMD declared a quarterly dividend on its Series A cumulative perpetual preferred stock. The company also announced a partnership with AT&T that will provide free memberships, with the potential to convert some users into paying patients. These developments come as the common stock trades near its recent support level and the firm carries a high trailing P/E.
LifeMD Announces Preferred Dividend and AT&T Partnership. LifeMD declared a quarterly dividend on its Series A cumulative perpetual preferred stock. The company also announced a partnership with AT&T that will provide free memberships, with the potential to convert some users into paying patients. These developments come as the common stock trades near its recent support level and the firm carries a high trailing P/E.